Cardiac Fibrosis - Pipeline Review, H1 2013
Published: Apr-2013 | Format: PDF | Global Markets Direct | Number of pages: 36 | Code: MRS - 977
Global Markets Direct’s, 'Cardiac Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiac Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis.
Cardiac Fibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
A snapshot of the global therapeutic scenario for Cardiac Fibrosis.
A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Cardiac Fibrosis pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.
Reasons to buy
Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
Number of Products Under Development for Cardiac Fibrosis, H1 2013
Products under Development for Cardiac Fibrosis – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Merck & Co., Inc., H1 2013
BioLineRx, Ltd., H1 2013
Digna Biotech, S.L., H1 2013
miRagen Therapeutics, Inc., H1 2013
Fibrotech Therapeutics Pty. Ltd., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Cardiac Fibrosis Therapeutics – Drug Profile Updates
Cardiac Fibrosis Therapeutics – Dormant Products
Inquiry For Buying
COVID-19 Pandemic Impacts
Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.
Medical QMS Software-United States Market Status and Trend Report 2020-2025
Medical QMS Software-India Market Status and Trend Report 2020-2025
Medical QMS Software-China Market Status and Trend Report 2020-2025
Medical QMS Software-Asia Pacific Market Status and Trend Report 2020-2025
Medical QMS Software-EMEA Market Status and Trend Report 2020-2025View More
No Celebration; No Champagne; Champagne Sales Fizzling
The whole world is fighting against coronavirus. People are getting infected; people are dying; pe
UK’s Biggest Solar Plant gets Approval
UKs largest solar has got a go-ahead; the farm that stretches about 900 acres on the north Kent co
Warnings from Microsoft on COVID-19 Cyber-Scams
Microsoft has cautioned about the new phishing scam that is taking place by using the keyword COVI
Plans to Deliver the Prescriptions Using Self-Driving Cars
Cases of COVID-19 are increasing rapidly around the world. Different countries are implementing di
Cancer Diagnoses Has Declined Considerably Amidst Coronavirus
Health experts have started to raise concerns about the decline in people undergoing cancer screen